Jacob Laubach is an Oncology physician affiliated with Harvard University. OpenAlex indexes 532 publications with 19,085 citations (h-index 64); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
44 Binney St
D1b30
Boston, MA 021156013
Telephone
617-632-2127Registry record last updated 7 Mar 2023.
Clinical trials
- Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Sponsor: Jacob Laubach, MD
- Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Sponsor: Alliance Foundation Trials, LLC.
- An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Sponsor: Dana-Farber Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20251 payment
- Celgene CorporationProgram year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65%Thalidomide Analog56.4%Revlimid67%Pomalyst33%Part D≥34 patientsProteasome Inhibitor8.6%Ninlaro100%Part D<11 patientsDermatology
14.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.1%Acyclovir100%Part D≥14 patientsAnti-infectives
13.5%Short-acting sulfonamides13.5%Sulfamethoxazole-Trimethoprim100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
New England Journal of Medicine
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Felipe Fregni, MD, MPH
Harvard University
Joseph Antin, MD
Harvard University
Sarah Fortune, MD
Harvard University
Elizabeth Buchbinder, MD
Harvard University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”